Disease · MONDO_0005575

colorectal cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. colorectal cancer. Diseases, record MONDO_0005575. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005575

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: colorectal cancer; Open Targets
Open Targets ID: MONDO_0005575; Open Targets
Other names: cancer of colorectum, cancer of large bowel, cancer of large intestine, cancer of the large bowel, colon cancer, advanced, somatic, colon cancer, somatic, colorectal cancer with chromosomal instability, somatic, colorectal cancer, autosomal dominant, somatic mutation, colorectal cancer, somatic, colorectal cancer, susceptibility to, autosomal dominant, somatic mutation, colorectum cancer, malignant colorectal neoplasm, malignant colorectal tumor, malignant colorectal tumour, malignant colorectum neoplasm, malignant large bowel neoplasm, malignant large bowel tumor, malignant large bowel tumour, malignant large intestine neoplasm, malignant large intestine tumor, malignant large intestine tumour, malignant neoplasm of colorectum, malignant neoplasm of large bowel, malignant neoplasm of large intestine, malignant neoplasm of the large bowel, malignant neoplasm of the large intestine, malignant tumor of large bowel, malignant tumor of large intestine, malignant tumor of the large bowel, malignant tumor of the large intestine, malignant tumour of large bowel, malignant tumour of large intestine, malignant tumour of the large bowel, malignant tumour of the large intestine; Open Targets
Disease Ontology: DOID:5672; Disease Ontology
Disease Ontology: DOID:9256; Disease Ontology
NCI Thesaurus: C4978; NCI Thesaurus
Orphanet: ORPHA:466667; Orphanet
Highest stage of its drugs: Approval, for 20 of its 741 drugs, from ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD; Open Targets

Drugs741

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Approval	TTD	538	537	485	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Approval	TTD	475	474	432	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	PMDA	446	443	442	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Approval	TTD	342	341	322	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Approval	TTD	321	320	318	Drugs and targets
PANITUMUMAB	CHEMBL1201827	Antibody	Approval	PMDA and TTD	115	113	111	Drugs and targets
REGORAFENIB	CHEMBL1946170	Small molecule	Approval	DailyMed and PMDA	106	104	104	Drugs and targets
TRIFLURIDINE	CHEMBL1129	Small molecule	Approval	ClinicalTrials.gov, FDA and PMDA	91	88	83	Drugs and targets
FRUQUINTINIB	CHEMBL4303214	Small molecule	Approval	TTD	89	88	86	Drugs and targets
TIPIRACIL	CHEMBL235668	Small molecule	Approval	ClinicalTrials.gov	63	63	62	Drugs and targets

1 to 10 of 741

See all 741 drugs

Targets531

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	31	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
EGFR	Epidermal growth factor receptor	28	Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 negative allosteric modulator; Epidermal growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	25	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	24	Vascular endothelial growth factor receptor 1 antagonist; Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	22	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	21	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	21	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
ERBB2	Epidermal growth factor receptor	17	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator; Receptor tyrosine-protein kinase erbB-2 binding agent	Phase 3	https://conductscience.org/library/genes/2064	Drugs and targets
TUBA1A	Tubulin	16	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	16	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 531

See all 531 targets

Trials2,239

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 44 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00112918	Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer	Phase 3	3,451	2012-09-06	Colorectal Cancer	BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02089737	Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)		3,091	2017-04-06	Advanced or Recurrent Colorectal Cancer	PANITUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00265850	Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Phase 3	2,334	2017-04-26	Colorectal Cancer	BEVACIZUMAB, CETUXIMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00069095	A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer	Phase 3	2,035	2016-01-22	Colorectal Cancer	BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00384176	First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX	Phase 2/3	1,814	2012-11-28	Colorectal Cancer	CEDIRANIB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00399035	Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer	Phase 3	1,254	2012-10-30	Metastatic Colorectal Cancer	CEDIRANIB	Its record names the disease	ClinicalTrials.gov
NCT02753127	A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer	Phase 3	1,253	2022-04-26	Colorectal Cancer	FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM, NAPABUCASIN	Its record names the disease	ClinicalTrials.gov
NCT00561470	Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen	Phase 3	1,226	2012-09-28	Colorectal Neoplasms, Neoplasm Metastasis	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00154102	Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)	Phase 3	1,221	2011-02-23	Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer	CETUXIMAB, FLUOROURACIL, FOLINIC ACID, IRINOTECAN	Its record names the disease	ClinicalTrials.gov
NCT00364013	PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy	Phase 3	1,183	2014-03-28	Metastatic Colorectal Cancer	FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PANITUMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 2,239

See all 2,239 trials

Comparisons in its trials324

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Panitumumab vs Concomitant Administration of Panitumumab and Chemotherapy: serious adverse events	614 of 1,254	747 of 1,831	3,085	NCT02089737	Trial comparisons
Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause	507 of 624	499 of 629	1,253	NCT02753127	Trial comparisons
Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events	234 of 622	201 of 610	1,232	NCT02753127	Trial comparisons
Aflibercept/FOLFIRI vs Placebo/FOLFIRI: serious adverse events	294 of 611	198 of 605	1,216	NCT00561470	Trial comparisons
Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Safety - Number of Patients Experiencing Any Adverse Event	599 of 600	597 of 602	1,202	NCT00154102	Trial comparisons
Cetuximab Plus FOLFIRI vs FOLFIRI Alone: serious adverse events	263 of 600	204 of 602	1,202	NCT00154102	Trial comparisons
Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Participants With No Residual Tumor After Metastatic Surgery	29 of 599	10 of 599	1,198	NCT00154102	Trial comparisons
Panitumumab Plus FOLFOX vs FOLFOX Alone: serious adverse events	262 of 585	198 of 584	1,169	NCT00364013	Trial comparisons
Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events	98 of 559	111 of 578	1,137	NCT00265850	Trial comparisons
FOLFIRI + Ramucirumab vs FOLFIRI + Placebo: serious adverse events	198 of 529	175 of 528	1,057	NCT01183780	Trial comparisons

1 to 10 of 324

See all 324 comparisons in its trials

Papers from its trials1,095

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41747221	RESULT	1	PubMed
41407398	RESULT	1	PubMed
40739424	RESULT	1	PubMed
40437949	RESULT	1	PubMed
40285503	RESULT	1	PubMed
40140925	RESULT	1	PubMed
39792482	RESULT	1	PubMed
39475591	RESULT	2	PubMed
39093546	RESULT	1	PubMed
39036382	RESULT	1	PubMed

1 to 10 of 1,095

See all 1,095 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005575

GET https://conductscience.org/api/diseases/v1/MONDO_0005575/drugs?page=2

API reference For AI assistants